Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN KEMPERS

NPI
1003852427
CMS profile
237
Location
FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$197.59

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $197.59 3

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $125.00 1
Acrotech Biopharma LLC $42.44 1
Janssen Research & Development, LLC $30.15 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN KEMPERS

NPI 1003852427 · CMS profile ID 237

FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003852427?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003852427?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003852427?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1003852427?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $197.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Acrotech Biopharma LLC $42.4412/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937455263 CMS
Janssen Research & Development, LLC $30.1503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887129459 CMS
Incyte Corporation $125.0003/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943006117 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $487.41 9
PY2020 $2,100.00 1
PY2021 $45.00 1
PY2022 $197.59 3
PY2023 $8,088.76 14
PY2024 $2,182.90 6
PY2025 $2,500.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $625,552.01 94
PY2024 Principal investigator $714,642.60 239
PY2023 Principal investigator $556,939.59 143
PY2022 Recipient $155.00 1
PY2022 Principal investigator $633,017.42 68
PY2021 Recipient $29,455.27 2
PY2021 Principal investigator $881,507.91 62
PY2020 Principal investigator $539,612.47 58
PY2019 Recipient $15,973.75 2
PY2019 Principal investigator $1,131,652.54 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534555
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,800.00 12/26/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center (Mcsc)
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235995673
Principal investigator 1 Janssen Research & Development, LLC $4,046.00 12/25/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365142
Principal investigator 1 Incyte Corporation $1,185.50 12/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557866
Principal investigator 1 ABBVIE INC. $2,167.50 12/04/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202528482
Principal investigator 1 Vanda Pharmaceuticals Inc. $12,375.00 12/03/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232947087
Principal investigator 1 Janssen Research & Development, LLC $4,046.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365157
Principal investigator 1 Janssen Research & Development, LLC $1,651.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175365227
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,831.57 12/01/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288979
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,249.19 12/01/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289037
Principal investigator 1 Vanda Pharmaceuticals Inc. $10,000.00 11/24/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946984
Principal investigator 1 Incyte Corporation $47.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557844
Principal investigator 1 Incyte Corporation $47.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557850
Principal investigator 1 Incyte Corporation $1,935.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557856
Principal investigator 1 Incyte Corporation $1,935.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557861
Principal investigator 1 Incyte Corporation $1,825.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557871
Principal investigator 1 Incyte Corporation $1,825.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557877
Principal investigator 1 Incyte Corporation $1,804.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557883
Principal investigator 1 Incyte Corporation $128.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557891
Principal investigator 1 Incyte Corporation $128.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557895
Principal investigator 1 Incyte Corporation $2,645.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557914
Principal investigator 1 Incyte Corporation $2,645.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557919
Principal investigator 1 Incyte Corporation $2,645.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557924
Principal investigator 1 Incyte Corporation $2,645.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557929
Principal investigator 1 Incyte Corporation $542.50 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557935
Principal investigator 1 Incyte Corporation $1,728.00 11/19/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557941
Principal investigator 1 Incyte Corporation $4,925.00 11/05/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557902
Principal investigator 1 ABBVIE INC. $11,182.50 11/04/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202520945
Principal investigator 1 Janssen Research & Development, LLC $3,302.00 10/31/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175365193
Principal investigator 1 Janssen Research & Development, LLC $2,211.00 10/31/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175365238
Principal investigator 1 Vanda Pharmaceuticals Inc. $17,083.00 10/28/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946770
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,840.78 10/27/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163704
Principal investigator 1 Janssen Research & Development, LLC $7,282.00 10/24/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365214
Principal investigator 1 Eli Lilly and Company $17,110.00 10/21/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187875985
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,887.68 10/09/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163702
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $13,686.75 10/08/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433293
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,834.74 10/08/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286495
Principal investigator 1 Vanda Pharmaceuticals Inc. $21,200.00 10/03/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946448
Principal investigator 1 Incyte Corporation $8,000.00 10/02/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557834
Principal investigator 1 Incyte Corporation $1,000.00 10/02/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557839
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240557907
Principal investigator 1 Janssen Research & Development, LLC $4,046.00 09/29/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365201
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,561.50 09/26/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,681.76 09/26/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285997
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,156.93 09/12/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163700
Principal investigator 1 Janssen Research & Development, LLC $4,046.00 09/08/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365293
Principal investigator 1 Janssen Research & Development, LLC $6,306.00 09/04/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175365207
Principal investigator 1 Vanda Pharmaceuticals Inc. $39,456.00 09/04/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946240
Principal investigator 1 ABBVIE INC. $7,590.00 09/03/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508298
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,669.48 08/15/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284341
Principal investigator 1 Janssen Research & Development, LLC $3,900.00 08/07/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365270
Principal investigator 1 Vanda Pharmaceuticals Inc. $14,805.00 08/06/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946067
Principal investigator 1 Vanda Pharmaceuticals Inc. $42,620.00 08/06/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946071
Principal investigator 1 ABBVIE INC. $10,702.50 08/05/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202501090
Principal investigator 1 ABBVIE INC. $1,500.00 08/05/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202502228
Principal investigator 1 Janssen Research & Development, LLC $1,856.00 08/04/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175365264
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,580.04 08/01/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283685
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,941.80 08/01/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283687
Principal investigator 1 Janssen Research & Development, LLC $16,352.00 07/28/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365149
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $17,795.93 07/15/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433285
Principal investigator 1 Janssen Research & Development, LLC $1,651.00 06/26/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175365300
Principal investigator 1 Janssen Research & Development, LLC $6,528.00 06/23/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365285
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,632.55 06/13/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281248
Principal investigator 1 ABBVIE INC. $8,400.00 06/03/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202489113
Principal investigator 1 Arcutis Biotherapeutics, Inc. $9,000.00 05/23/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163698
Principal investigator 1 Janssen Research & Development, LLC $3,095.00 05/22/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175365166
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,822.41 05/21/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280078
Principal investigator 1 Janssen Research & Development, LLC $2,626.00 05/09/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175365219
Principal investigator 1 ABBVIE INC. $13,518.75 05/07/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202482639
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,265.02 04/28/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232945314
Principal investigator 1 Janssen Research & Development, LLC $7,650.00 04/11/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175365250
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,118.75 04/11/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433281
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,646.70 04/11/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277994
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $136.00 04/07/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433277
Principal investigator 1 ABBVIE INC. $12,330.00 04/03/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202472264
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $20,089.50 03/27/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1235995675
Principal investigator 1 Janssen Research & Development, LLC $2,517.00 03/27/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175365183
Principal investigator 1 ABBVIE INC. $1,968.41 03/25/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202465828
Principal investigator 1 ABBVIE INC. $21,273.50 03/20/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202465273
Principal investigator 1 ABBVIE INC. $7,320.00 03/07/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202461652
Principal investigator 1 Janssen Research & Development, LLC $4,961.00 03/06/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175365175
Principal investigator 1 Janssen Research & Development, LLC $5,034.00 03/03/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175365257
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,468.80 02/26/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275593
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,807.56 02/14/2025 Non-covered Recipient Entity
Associated Skin Care Specialists
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235998858
Principal investigator 1 ABBVIE INC. $6,705.00 02/06/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202447649
Principal investigator 1 ABBVIE INC. $3,000.00 02/06/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,234.40 02/03/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274605
Principal investigator 1 Janssen Research & Development, LLC $8,144.00 01/31/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175365276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,462.82 01/24/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274451
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $21,895.43 01/22/2025 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433272
Principal investigator 1 ABBVIE INC. $2,200.00 01/20/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202440059
Principal investigator 1 ABBVIE INC. $2,715.00 01/20/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202440063
Principal investigator 1 Eli Lilly and Company $6,658.80 01/03/2025 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187875527
Principal investigator 1 Amgen Inc. $1,650.60 01/02/2025 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
P2 Moderate-Severe pDLE No dispute reported 06/30/2026 1246644763